Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Letter to Shareholders: Acology 10Q Highlights, End of Year Plans


Posted on: 09 Nov 17
  • Tracking Best Sales Year in Company History
  • Well Prepared for Huge Upside for 2018

CORONA, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Acology Inc. From the Desk of Curt Fairbrother

Dear Shareholders:

As promised before the end of this calendar year we wanted to share with you some of our most recent success. Our 10Q, published yesterday, details our highest gross profit to date and we’re tracking even larger increases before the end of the year. Our gross profit increased as our product costs lowered. Acology’s balance sheet has been relieved of more than $1M in debt as our other expenses have dramatically decreased.

Our new product lines are accounting for much of this increase in total sales and our inventories have more than doubled in preparation for the multi-billion dollar increase that’s expected from the 2018 cannabis market. In short, Acology is very well positioned for the paradigm shift that’s coming next year. As the year ends we are close to completing arrangements with EZ Health Solutions and the new markets that will open for us in the CBD line.

Acology’s main purpose has always been to associate with excellent business partners that can move the proverbial needle, and we’ve succeeded in that throughout the past year. The sales success of 2017, coupled with our strong financial performance, our product diversity, our more than 4,000 world-wide distributors and the approach of the biggest cannabis market in history has inspired extreme confidence and great anticipation for the New Year.

As always, we are extremely grateful for you confidence and support. We wish the best for you and yours for the upcoming holiday season and look forward to sharing great accomplishments with you in 2018!

Sincerely,

Curt Fairbrother, CEO

Please visit Acology Inc. and D&C Distributors online or by phone. The company is located in their production and distribution facility at 1620 Commerce St. Corona, California, 92880.

Acology trades on the OTC under the call letters ACOL. The company’s websites are www.Acologyinc.com for the hospice and palliative care industry and www.themedtainer.com for the recreational and medical marijuana industry. Orders for Acology products can be taken online and by phone. Custom orders are especially welcome. Please send any and all inquiries to info@acologyinc.com or call (844) ACOLOGY (844-226-5649).

This press release includes statements that are covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events they are subject to risks and uncertainties and actual results for fiscal year 2016 and beyond could differ materially from the company’s current expectations. Forward-looking statements are identified by such words as “anticipates”, “projects”, “expects”, “planned”, “intends” and “believes” “estimate” “targets” and other similar expressions that indicate trends and future events. It is understood that investment entails risk on the part of the investor and could result in the loss of some or all of his or her investment.

GlobeNewswire
globenewswire.com

Last updated on: 09/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.